Traumatic brain injury induces long-lasting changes in immune and regenerative signaling.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 09 12 2018
accepted: 19 03 2019
entrez: 4 4 2019
pubmed: 4 4 2019
medline: 18 1 2020
Statut: epublish

Résumé

There are no existing treatments for the long-term degenerative effects of traumatic brain injury (TBI). This is due, in part, to our limited understanding of chronic TBI and uncertainty about which proposed mechanisms for long-term neurodegeneration are amenable to treatment with existing or novel drugs. Here, we used microarray and pathway analyses to interrogate TBI-induced gene expression in the rat hippocampus and cortex at several acute, subchronic and chronic intervals (24 hours, 2 weeks, 1, 2, 3, 6 and 12 months) after parasagittal fluid percussion injury. We used Ingenuity pathway analysis (IPA) and Gene Ontology enrichment analysis to identify significantly expressed genes and prominent cell signaling pathways that are dysregulated weeks to months after TBI and potentially amenable to therapeutic modulation. We noted long-term, coordinated changes in expression of genes belonging to canonical pathways associated with the innate immune response (i.e., NF-κB signaling, NFAT signaling, Complement System, Acute Phase Response, Toll-like receptor signaling, and Neuroinflammatory signaling). Bioinformatic analysis suggested that dysregulation of these immune mediators-many are key hub genes-would compromise multiple cell signaling pathways essential for homeostatic brain function, particularly those involved in cell survival and neuroplasticity. Importantly, the temporal profile of beneficial and maladaptive immunoregulatory genes in the weeks to months after the initial TBI suggests wider therapeutic windows than previously indicated.

Identifiants

pubmed: 30943276
doi: 10.1371/journal.pone.0214741
pii: PONE-D-18-35208
pmc: PMC6447179
doi:

Substances chimiques

Acute-Phase Proteins 0
NF-kappa B 0
NFATC Transcription Factors 0
Toll-Like Receptors 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0214741

Déclaration de conflit d'intérêts

The support of MTF and KEOT by GenUs Biosystems and Paradise Genomics, Inc. does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Références

Br J Pharmacol. 2016 Feb;173(4):681-91
pubmed: 25939377
Biol Proced Online. 2006;8:175-93
pubmed: 17242735
Annu Rev Neurosci. 2012;35:369-89
pubmed: 22715882
J Neurosci. 2018 Mar 7;38(10):2519-2532
pubmed: 29437855
Front Neurol. 2013 Mar 04;4:18
pubmed: 23459929
Restor Neurol Neurosci. 2014;32(2):337-65
pubmed: 24398724
Brain Sci. 2017 Jul 12;7(7):
pubmed: 28704928
Neurotherapeutics. 2015 Jan;12(1):143-50
pubmed: 25421001
Behav Brain Res. 2018 Mar 15;340:137-146
pubmed: 28042008
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Sci Rep. 2017 Jul 27;7(1):6645
pubmed: 28751711
Vet Pathol. 2013 Jan;50(1):7-22
pubmed: 23345459
Drugs Today (Barc). 2018 Jun;54(6):349-360
pubmed: 29998226
Sci Rep. 2016 Aug 17;6:31570
pubmed: 27530814
Lipids Health Dis. 2013 Feb 11;12:16
pubmed: 23398903
Science. 2006 Aug 25;313(5790):1093-7
pubmed: 16931756
Neurotox Res. 2012 Feb;21(2):175-84
pubmed: 21735317
Neuroscience. 2010 Dec 29;171(4):1273-82
pubmed: 20950674
PLoS One. 2013;8(1):e53230
pubmed: 23326402
J Neuroinflammation. 2018 Mar 5;15(1):68
pubmed: 29506554
J Neuroinflammation. 2017 Sep 13;14(1):186
pubmed: 28903766
Neurobiol Dis. 2013 Jun;54:252-63
pubmed: 23313314
Nat Rev Neurol. 2011 Jan;7(1):31-40
pubmed: 21135885
Metab Brain Dis. 2015 Jun;30(3):747-54
pubmed: 25413451
Cell. 2010 Mar 19;140(6):918-34
pubmed: 20303880
CNS Drugs. 2012 Feb 1;26(2):111-21
pubmed: 22296315
J Neurotrauma. 2018 Oct 1;35(19):2317-2329
pubmed: 29463176
Medicine (Baltimore). 2018 Sep;97(37):e12018
pubmed: 30212930
Inflammation. 2018 Mar;41(2):449-463
pubmed: 29198014
PLoS One. 2011;6(8):e23111
pubmed: 21853077
Front Neurol. 2013 Jan 17;3:186
pubmed: 23335911
Brain Res Mol Brain Res. 2004 Mar 17;122(1):47-61
pubmed: 14992815
Science. 2015 Nov 27;350(6264):1096-101
pubmed: 26472758
J Neurosci. 1995 Dec;15(12):8223-33
pubmed: 8613756
J Neurotrauma. 2003 Oct;20(10):907-27
pubmed: 14588109
BMB Rep. 2018 Feb;51(2):92-97
pubmed: 29335071
Int Rev Neurobiol. 2009;85:351-62
pubmed: 19607980
J R Soc Interface. 2009 Aug 6;6(37):655-68
pubmed: 18986963
J Alzheimers Dis. 2017;57(3):667-681
pubmed: 28269777
J Cell Sci. 2018 Jan 10;131(1):
pubmed: 29222111
PLoS One. 2015 May 27;10(5):e0127287
pubmed: 26016641
Cell Syst. 2016 Apr 27;2(4):239-250
pubmed: 27135536
Front Syst Neurosci. 2016 Jan 26;9:190
pubmed: 26858612
Nat Biotechnol. 2010 Aug;28(8):827-38
pubmed: 20676074
Neurosci Biobehav Rev. 2015 Nov;58:123-46
pubmed: 25496906
Lancet Neurol. 2017 Dec;16(12):987-1048
pubmed: 29122524
Cell Mol Life Sci. 2015 Nov;72(21):4027-47
pubmed: 26190021
BMC Neurosci. 2017 Mar 7;18(1):30
pubmed: 28270094
Biomark Insights. 2015 May 12;10(Suppl 1):43-60
pubmed: 25983552
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
PLoS One. 2011;6(9):e24680
pubmed: 21931809
Drug Discov Today. 2015 Aug;20(8):920-3
pubmed: 25701283
Oncol Lett. 2018 Jun;15(6):8245-8252
pubmed: 29805558
Front Neurol. 2016 Nov 22;7:198
pubmed: 27920753
Gene Expr. 2010;15(1):1-11
pubmed: 21061913
J Clin Neurosci. 2000 Mar;7(2):137-40
pubmed: 10844800
Future Oncol. 2017 Oct;13(23):2053-2063
pubmed: 28984474
Int J Mol Sci. 2014 Apr 15;15(4):6378-90
pubmed: 24739809
PLoS One. 2014 Feb 11;9(2):e88889
pubmed: 24523945
Cell Rep. 2016 Mar 1;14(8):1930-9
pubmed: 26904943
Front Mol Neurosci. 2015 Dec 18;8:77
pubmed: 26733801
J Neurosci Methods. 2016 Oct 15;272:38-49
pubmed: 27382003
Cell Metab. 2015 Oct 6;22(4):658-68
pubmed: 26321659
Trends Immunol. 2008 Aug;29(8):357-65
pubmed: 18599350
Proteomics. 2018 Jun;18(11):e1700321
pubmed: 29645351
J Neuroinflammation. 2012 Jan 25;9:23
pubmed: 22277195
J Immunol. 2008 Sep 1;181(5):3373-83
pubmed: 18714009
Neural Regen Res. 2018 Oct;13(10):1693-1704
pubmed: 30136679
Int J Mol Sci. 2014 Jan 17;15(1):1216-36
pubmed: 24445258
J Neurotrauma. 2017 Mar 1;34(5):1086-1096
pubmed: 27650266
Neuroscience. 1998 Nov;87(2):359-69
pubmed: 9740398
Brain Struct Funct. 2014 Jan;219(1):193-209
pubmed: 23232826
Nature. 2017 Nov 23;551(7681):427-431
pubmed: 29168817
J Immunol. 2004 Jul 15;173(2):715-20
pubmed: 15240655
Physiol Rev. 2004 Jan;84(1):87-136
pubmed: 14715912
Curr Opin Crit Care. 2007 Apr;13(2):134-42
pubmed: 17327733
Curr Top Med Chem. 2018;18(16):1416-1421
pubmed: 30129414
Br J Anaesth. 2007 Jul;99(1):4-9
pubmed: 17573392
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Methods Mol Biol. 2010;662:303-16
pubmed: 20824478
Curr Neuropharmacol. 2018 Jan 30;16(2):176-209
pubmed: 28847294
PLoS Med. 2018 Jan 30;15(1):e1002496
pubmed: 29381704
Mol Neurodegener. 2013 Oct 12;8:40
pubmed: 24119288
Lancet. 2001 Oct 6;358(9288):1174-6
pubmed: 11597694
Exp Neurol. 2007 Mar;204(1):20-8
pubmed: 17059819
J Immunol. 2014 Mar 1;192(5):2339-48
pubmed: 24489093
Nat Biotechnol. 2006 Sep;24(9):1151-61
pubmed: 16964229
J Neuroinflammation. 2017 Jan 13;14(1):10
pubmed: 28086980
Arch Phys Med Rehabil. 2015 Apr;96(4):754-9
pubmed: 25433219

Auteurs

Deborah R Boone (DR)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Harris A Weisz (HA)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Hannah E Willey (HE)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Karen E O Torres (KEO)

GenUs Biosystems, Northbrook, Illinois, United States of America.

Michael T Falduto (MT)

GenUs Biosystems, Northbrook, Illinois, United States of America.
Paradise Genomics, Inc., Northbrook, Illinois, United States of America.

Mala Sinha (M)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Heidi Spratt (H)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Ian J Bolding (IJ)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Kathea M Johnson (KM)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Margaret A Parsley (MA)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Douglas S DeWitt (DS)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Donald S Prough (DS)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Helen L Hellmich (HL)

Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas, United States of America.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH